You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2024

Litigation Details for Biogen Inc. v. Sandoz Inc. (D. Del. 2022)


✉ Email this page to a colleague

« Back to Dashboard


Biogen Inc. v. Sandoz Inc. (D. Del. 2022)

Docket ⤷  Subscribe Date Filed 2022-09-09
Court District Court, D. Delaware Date Terminated
Cause 35:271 Patent Infringement Assigned To Gregory B. Williams
Jury Demand None Referred To
Parties SANDOZ INC.; SANDOZ INTERNATIONAL GMBH
Patents 10,119,976; 10,233,245; 6,509,376; 6,602,503; 7,320,999; 7,619,001; 7,803,840; 8,124,350; 8,399,514; 8,871,449; 9,493,567; 9,709,575
Attorneys Matthew A. Chivvis; Theresa Tan
Firms Morris, Nichols, Arsht & Tunnell; Young, Conaway, Stargatt & Taylor LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Biogen Inc. v. Sandoz Inc.
The small molecule drug covered by the patents cited in this case is ⤷  Subscribe .
Biologic Drugs cited in Biogen Inc. v. Sandoz Inc.
The biologic drugs covered by the patents cited in this case are ⤷  Subscribe and ⤷  Subscribe .

Details for Biogen Inc. v. Sandoz Inc. (D. Del. 2022)

Date Filed Document No. Description Snippet Link To Document
0000-00-00 External link to document
2022-09-19 10 Redacted Document the ’845 patent is attached as Exhibit 3.  U.S. Patent No. U.S. 10,119,976 118… 118. U.S. Patent No. 10,119,976 (“the ’976 patent”), entitled “Method of Assessing Risk of PML,”…and Declaration of Infringement of U.S. Patent No. 10,119,976) 217. Biogen re-alleges and…Page 2 of 107 PageID #: 1325 9,790,533; U.S. 10,119,976; U.S. 10,233,245; U.S. 10,308,706; U.S. 10,444,234…covered by US Patent claims and corresponding patent claims outside the US. The foregoing patent claims are External link to document
2023-02-23 136 Redacted Document 10,119,976, and U.S. Patent No. 11,280,794 for purposes of discovery for the preliminary injunction… the methods described in U.S. Patent Nos. 10,119,976 and 11,280,794, including whether Biogen… whether Biogen has marked that U.S. Patent Nos. 10,119,976 and 11,280,794 cover methods used by …including United States Patent Nos. 9,096,879; 10,844,416; 9,316,641; 10,119,976; and 11,280,794. …practice of the asserted claims of U.S. Patent Nos. 10,119,976 and 11,280,794 and how often and in External link to document
2022-12-08 56 Redacted Document the ’845 patent is attached as Exhibit 3.  U.S. Patent No. U.S. 10,119,976 110… 110. U.S. Patent No. 10,119,976 (“the ’976 patent”), entitled “Method of Assessing Risk of PML,”… (Declaration of Infringement of U.S. Patent No. 10,119,976) 191. Biogen re-alleges and…,567; U.S. 10,233,245; U.S. 11,292,845; U.S. 10,119,976; U.S. 10,677,803; U.S. 11,280,794; U.S. 9,316,641…covered by US Patent claims and corresponding patent claims outside the US. The foregoing patent claims are External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.